GLP-1 agonist exposure around conception: no clear signal, but thin evidence

Design

Narrative review, non-systematic search of PubMed, Embase and other databases

Population

Preclinical studies and human reports of GLP-1 agonist exposure from preconception to the postnatal period

Primary outcome

Congenital anomalies, hypertensive disorders, gestational diabetes, preterm birth, fetal growth, stillbirth, washout

Effect

No clear increase in adverse outcomes in observational data; evidence insufficient to exclude important risk

A narrative review in BJOG gathered the preclinical and human data on women exposed to GLP-1 receptor agonists shortly before conception or during early pregnancy. It was a non-systematic search, so what it offers is a map of the evidence rather than a pooled estimate.

The human observational data it reviewed did not show a clear rise in adverse pregnancy outcomes after periconception exposure. The authors are explicit that numbers are small, exposure is often recorded incompletely and confounding is likely. These drugs also appear to improve fertility in some women with obesity and polycystic ovary syndrome, which is why unplanned pregnancies are being seen more often.

In clinic, the useful step is to ask about these drugs at booking and at preconception visits, since enquiry is not routine. For a woman who conceives while on one, the review argues for individual counselling that says neither that harm is established nor that safety is proven.

• Ask about GLP-1 receptor agonist use at booking and preconception visits, including prescriptions from other doctors.
• Record the drug, the dose and when the last dose was taken.
• Counsel that observational data show no clear harm so far, but are too limited to rule out important risk.
• Review whether the drug is still needed and whether contraception advice was given when it was started.
• Consider reporting the exposure to a pregnancy registry or pharmacovigilance system if one is available locally.

Why it matters

Maternity teams will meet more of these exposures, and the honest counselling message sits between reassurance and alarm.

Don't overread it

A narrative review with a non-systematic search cannot establish safety; it summarises limited observational evidence.

The statistics, in plain English

This review reports no pooled numbers. 'No clear signal' in small observational studies means the studies could not detect a difference, not that no difference exists. Missed exposure and confounding by obesity and diabetes can push results in either direction.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.